drugset / Trial / NCT00563706
Study Evaluating Vabicaserin in Subjects With Schizophrenia
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary purpose of this protocol is to establish the efficacy, safety, and tolerability of vabicaserin (SCA-136) using a once a day capsule in subjects with acute exacerbations of schizophrenia.
Timeline
- Start
- 2007-12
- Primary completion
- 2008-06
- Completion
- 2008-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Risperidone | Other / unclassified | 4 mg | — |
| Subject | vabicaserin | Small molecule | 50 mg | Oral |
| Subject | vabicaserin | Small molecule | 100 mg | Oral |
| Subject | vabicaserin | Small molecule | 150 mg | Oral |
| Subject | vabicaserin | Small molecule | 200 mg | Oral |
| Subject | vabicaserin | Small molecule | 300 mg | Oral |
| Subject | vabicaserin | Small molecule | 400 mg | Oral |
| Subject | vabicaserin | Small molecule | 600 mg | Oral |